世界の抗体フラグメント市場2022-2030:特異性別(モノクローナル抗体、ポリクローナル抗体)、種類別、治療法別、用途別、地域別

【英語タイトル】Antibody Fragments Market Size, Share & Trends Analysis Report By Specificity (Monoclonal Antibodies, Polyclonal Antibodies), By Type, By Therapy, By Application, By Region, And Segment Forecasts, 2022 - 2030

Grand View Researchが出版した調査資料(GRV22SP096)・商品コード:GRV22SP096
・発行会社(調査会社):Grand View Research
・発行日:2022年8月25日
・ページ数:150
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,324,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Grand View Research社の最新調査レポートによると、世界の抗体フラグメント市場規模は2030年までに113.6憶ドルに達っし、2022年から2030年にかけて年平均5.9%成長すると予測されています。本書では、抗体フラグメントの世界市場を多面的に調査し、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、特異性別(モノクローナル抗体、ポリクローナル抗体)分析、種類別(FAB、scFv、sdAb、その他)分析、治療法別(モノクローナル抗体、プラックスバインド、ラニビズマブ、セルトリズマブペゴル、その他)分析、用途別(癌、免疫不全、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況など、以下の構成でお届けいたします。なお、本書に掲載されている企業情報には、Pfizer Inc、Sanofi、Albynx、Novartis AG、Genentech, Inc.、AbbVie Inc.、Bristol-Myers Squibb Company、Johnson & Johnson Services, Inc.、Lillyなどが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲

・世界の抗体フラグメント市場規模:特異性別
- モノクローナル抗体の市場規模
- ポリクローナル抗体の市場規模

・世界の抗体フラグメント市場規模:種類別
- FAB抗体フラグメントの市場規模
- scFv抗体フラグメントの市場規模
- sdAb抗体フラグメントの市場規模
- その他抗体フラグメントの市場規模

・世界の抗体フラグメント市場規模:治療法別
- モノクローナル抗体治療の市場規模
- プラックスバインド治療の市場規模
- ラニビズマブ治療の市場規模
- セルトリズマブペゴル治療の市場規模
- その他治療の市場規模

・世界の抗体フラグメント市場規模:用途別
- 癌用抗体フラグメントの市場規模
- 免疫不全用抗体フラグメントの市場規模
- その他用途の市場規模

・世界の抗体フラグメント市場規模:地域別
- 北米の抗体フラグメント市場規模
- ヨーロッパの抗体フラグメント市場規模
- アジア太平洋の抗体フラグメント市場規模
- 中南米の抗体フラグメント市場規模
- 中東・アフリカの抗体フラグメント市場規模

・競争状況

抗体フラグメント市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の抗体フラグメント市場規模は2030年までに113.6億米ドルに達し、2022年から2030年までの年平均成長率は5.9%で拡大する見込みです。高齢者人口の増加と社会行動の変化により、世界中で慢性疾患が着実に増加しています。都市化の進展は中間層の増加をもたらし、その結果、人々はより座りがちで不健康なライフスタイルを採用するようになり、糖尿病などの疾患の増加を引き起こしています。人口の大幅な増加により、患者負担が最も大きいのは新興市場であると予測されます。

さらに、主要市場プレーヤーによる投資の拡大が業界の成長に寄与しています。例えば、2020年6月、バンダービルト大学医療センターは、COVID-19の治療と予防のための可能性のある併用療法として、同社のコロナウイルス中和抗体の臨床開発を進めるためにアストラゼネカと提携しました。このような要因が、今後数年間の市場を牽引していくでしょう。

抗体は分子やタンパク質を検出するための重要なツールです。ほとんどのイムノアッセイアプリケーションでは全抗体が望ましいとはいえ、一部の実験ではF(ab’)2やFabなどの抗体断片によってのみ性能が向上します。モノクローナル抗体は、様々な癌の治療薬として承認されている重要な治療薬です。既に80以上の抗体が様々な疾患への適応で承認されており、これらの抗体はバイオ医薬品の中で最大のクラスです。より小型で抗原結合性の高い抗体フラグメントの導入が急ピッチで進んでおり、業界にプラスの影響を与えています。

抗体フラグメントは、製造・精製コストが低いため、全鎖抗体よりも好まれると予想されています。特定の疾患の治療に抗体フラグメントを使用することは、厳格なICD-10規則によって制約を受ける可能性があります。しかし、重篤な疾患に対する抗体フラグメントの臨床開発における新たな進歩は、大きな市場成長機会をもたらす可能性があります。

抗体フラグメント市場レポートハイライト

- 特異性別では、モノクローナル抗体が2021年に最大のシェアを獲得しました。

- タイプ別では、scFvセグメントが今後数年間で最も急成長すると予測されています。scFvは、多価性、異種生産性、低分子量、親MAbを超える多量体形状など、いくつかの利点を備えています。

- 治療法別では、モノクローナル抗体分野が2021年の市場をリード。ラニビズマブ(ルセンティス)は、糖尿病黄斑浮腫、血管新生(湿潤)加齢黄斑変性(AMD)などによる視力障害の治療に使用されるため、2021年に最大の売上シェアを獲得しました。

- 用途別では、世界的な癌の有病率の増加により、治療目的での抗体フラグメントの採用が増加していることから、癌分野が予測期間中に最も急成長する見込みです。

- 2021年には、免疫不全疾患の有病率の増加により、研究目的での抗体フラグメントの需要が増加している北米が市場を席巻しました。

- アジア太平洋地域は、バイオテクノロジーおよび製薬研究に対する民間および公的パートナーシップによる投資の増加により、将来的に大幅な成長が見込まれます。これが抗体フラグメントの採用に拍車をかけています。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Competition Milieu
1.3. Segment Outlook
Chapter 2. Research Methodology
2.1. Information Procurement
2.2. Information or Data Analysis
2.3. Market Formulation & Validation
Chapter 3. Antibody Fragments Market Variables, Trends & Scope
3.1. Parent Market Analysis
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of infectious and chronic diseases
3.2.1.2. Antibody fragments are preferred over other alternatives
3.2.1.3. Increasing public-private investments for pharma and biotech research
3.2.2. Market restraint analysis
3.2.2.1. Obstacles in the purification of antibody fragments
Chapter 4. Antibody Fragments Market: Segment Analysis, By Specificity, 2018 – 2030 (USD Million)
4.1. Definitions & Scope
4.2. Global Antibody Fragments Market, By Specificity, 2018 to 2030 (USD Million)
4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 USD Million
4.3.1. Monoclonal Antibodies
4.3.1.1. Global Antibody Fragments Market, Monoclonal Antibodies, 2018 to 2030 (USD Million)
4.3.2. Polyclonal Antibodies
4.3.2.1. Global Antibody Fragments Market, Monoclonal Antibodies, 2018 to 2030 (USD Million)
Chapter 5. Antibody Fragments Market: Segment Analysis, By Type, 2018 – 2030 (USD Million)
5.1. Definitions & Scope
5.2. Global Antibody Fragments Market, By Type, 2018 to 2030 (USD Million)
5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.3.1. FAB
5.3.1.1. Global Antibody Fragments Market, FAB, 2018 to 2030 (USD Million)
5.3.2. scFv
5.3.2.1. Global Antibody Fragments Market,scFv, 2018 to 2030 (USD Million)
5.3.3. sdAb
5.3.3.1. Global Antibody Fragments Market, sdAb, 2018 to 2030 (USD Million)
5.3.4. Others
5.3.4.1. Global Antibody Fragments Market, others, 2018 to 2030 (USD Million)
Chapter 6. Antibody Fragments Market: Segment Analysis, By Therapy, 2018 – 2030 (USD Million)
6.1. Definitions & Scope
6.2. Global Antibody Fragments Market, By Therapy, 2018 to 2030 (USD Million)
6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
6.3.1. Monoclonal Antibodies
6.3.2. Praxbind (idarucizumab)
6.3.2.1. Global Antibody Fragments Market, Praxbind (idarucizumab), 2018 to 2030 (USD Million)
6.3.3. Ranibizumab (Lucentis)
6.3.3.1. Global Antibody Fragments Market, Ranibizumab (Lucentis), 2018 to 2030 (USD Million)
6.3.4. Certolizumab pegol (Cimzia)
6.3.4.1. Global Antibody Fragments Market, Certolizumab pegol (Cimzia), 2018 to 2030 (USD Million)
6.3.5. Iodine (1311) Metuximab/ Licartin
6.3.5.1. Global Antibody Fragments Market, Iodine (1311) Metuximab/ Licartin, 2018 to 2030 (USD Million)
6.3.6. Beovu (brolucizumab-dbll)
6.3.6.1. Global Antibody Fragments Market, Beovu (brolucizumab-dbll), 2018 to 2030 (USD Million)
6.3.7. Cablivi (caplacizumab-yhdp)
6.3.7.1. Global Antibody Fragments Market, Cablivi (caplacizumab-yhdp), 2018 to 2030 (USD Million)
6.3.8. Blinatumomab/ Blincyto
6.3.8.1. Global Antibody Fragments Market, Blinatumomab/ Blincyto, 2018 to 2030 (USD Million)
6.3.9. PAB
6.3.10. CroFab
6.3.10.1. Global Antibody Fragments Market, CroFab, 2018 to 2030 (USD Million)
6.3.11. Anavip
6.3.11.1. Global Antibody Fragments Market, Anavip, 2018 to 2030 (USD Million)
6.3.12. Anascorp
6.3.12.1. Global Antibody Fragments Market, Anascorp, 2018 to 2030 (USD Million)
6.3.13. Botulism Antitoxin Heptavalent (HBAT)
6.3.13.1. Global Antibody Fragments Market, Botulism Antitoxin Heptavalent (HBAT), 2018 to 2030 (USD Million)
6.3.14. Digibind
6.3.14.1. Global Antibody Fragments Market, Digibind, 2018 to 2030 (USD Million)
6.3.15. DigiFab
6.3.15.1. Global Antibody Fragments Market, DigiFab, 2018 to 2030 (USD Million)
6.3.16. Pipeline
6.3.17. AFM13
6.3.17.1. Global Antibody Fragments Market, AFM13, 2018 to 2030 (USD Million)
6.3.18. HPN-424
6.3.18.1. Global Antibody Fragments Market, HPN-424, 2018 to 2030 (USD Million)
6.3.19. MGD007
6.3.19.1. Global Antibody Fragments Market, MGD007, 2018 to 2030 (USD Million)
6.3.20. Tebotelimab (MGD013)
6.3.20.1. Global Antibody Fragments Market, Tebotelimab (MGD013), 2018 to 2030 (USD Million)
6.3.21. Bentracimab (PB2452)
6.3.21.1. Global Antibody Fragments Market, Bentracimab (PB2452), 2018 to 2030 (USD Million)
6.3.22. Flotetuzumab (MGD006)
6.3.22.1. Global Antibody Fragments Market, Flotetuzumab (MGD006), 2018 to 2030 (USD Million)
6.3.23. AK104
6.3.23.1. Global Antibody Fragments Market, AK104, 2018 to 2030 (USD Million)
6.3.24. Ozoralizumab
6.3.24.1. Global Antibody Fragments Market, Ozoralizumab, 2018 to 2030 (USD Million)
6.3.25. Sonelokimab (ALX0761)
6.3.25.1. Global Antibody Fragments Market, Sonelokimab (ALX0761), 2018 to 2030 (USD Million)
Chapter 7. Antibody Fragments Market: Segment Analysis, By Application, 2018 – 2030 (USD Million)
7.1. Definitions & Scope
7.2. Global Antibody Fragments Market, By Application, 2018 to 2030 (USD Million)
7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
7.3.1. Cancer
7.3.1.1. Global Antibody Fragments Market, Cancer, 2018 to 2030 (USD Million)
7.3.2. Immunodeficiency
7.3.2.1. Global Antibody Fragments Market, Immunodeficiency, 2018 to 2030 (USD Million)
7.3.3. Others
7.3.3.1. Global Antibody Fragments Market, Others, 2018 to 2030 (USD Million)
Chapter 8. Antibody Fragments Market: Regional Market Analysis, By Region, 2018 – 2030 (USD Million)
8.1. Definitions & Scope
8.2. Regional market share analysis, 2021&2030
8.3. Regional Market Dashboard
8.4. Regional Market: Key Players
8.5. Market Size, & Forecasts, and Trend Analysis, 2018 to 2030
8.6. North America
8.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.6.5. U.S.
8.6.5.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.6.5.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.6.5.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.6.5.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.6.6. Canada
8.6.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.6.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.6.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.6.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7. Europe
8.7.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.5. Germany
8.7.5.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.5.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.5.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.5.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.6. U.K.
8.7.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.7. France
8.7.7.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.7.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.7.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.7.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.8. Italy
8.7.8.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.8.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.8.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.8.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.9. Spain
8.7.9.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.9.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.9.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.9.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.10. Russia
8.7.10.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.10.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.10.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.10.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8. Asia Pacific
8.8.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.5. China
8.8.5.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.5.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.5.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.5.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.6. Japan
8.8.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.7. India
8.8.7.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.7.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.7.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.7.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.8. Australia
8.8.8.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.8.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.8.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.8.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.9. South Korea
8.8.9.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.9.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.9.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.9.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.10. Singapore
8.8.10.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.10.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.10.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.10.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.9. Latin America
8.9.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.9.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.9.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.9.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.9.5. Mexico
8.9.5.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.9.5.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.9.5.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.9.5.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.9.6. Brazil
8.9.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.9.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.9.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.9.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.9.7. Argentina
8.9.7.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.9.7.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.9.7.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.9.7.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.10. Middle East & Africa
8.10.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.10.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.10.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.10.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.10.5. South Africa
8.10.5.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.10.5.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.10.5.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.10.5.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.10.6. Saudi Arabia
8.10.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.10.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.10.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.10.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.10.7. UAE
8.10.7.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.10.7.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.10.7.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.10.7.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Strategy Framework
9.2. Market Participation Categorization
9.3. Company Profile
9.3.1. Pfizer Inc
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Sanofi
9.3.2.1. Company Overview
9.3.2.1.1. Albynx
9.3.2.1.1.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Novartis AG
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Product Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Genentech, Inc.
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. AbbVie Inc.
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Bristol-Myers Squibb Company
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Johnson & Johnson Services, Inc.
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Lilly
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives



★調査レポート[世界の抗体フラグメント市場2022-2030:特異性別(モノクローナル抗体、ポリクローナル抗体)、種類別、治療法別、用途別、地域別] (コード:GRV22SP096)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の抗体フラグメント市場2022-2030:特異性別(モノクローナル抗体、ポリクローナル抗体)、種類別、治療法別、用途別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆